Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Expert Opin Ther Pat ; 25(1): 1-4, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25363310

ABSTRACT

In the upcoming case of Teva Pharmaceuticals v. Sandoz, the U.S. Supreme Court will address how much deference the appellate court should afford to a trial court's claim construction ruling. The effect of this decision will be far-reaching, as how claims are construed can determine whether a patent is infringed or not infringed, valid or invalid.


Subject(s)
Commerce/legislation & jurisprudence , Drug Industry/legislation & jurisprudence , Drug and Narcotic Control/legislation & jurisprudence , Drugs, Generic/supply & distribution , Immunosuppressive Agents/supply & distribution , Patents as Topic/legislation & jurisprudence , Peptides/supply & distribution , Commerce/economics , Drug Costs/legislation & jurisprudence , Drug Industry/economics , Drug and Narcotic Control/economics , Drugs, Generic/economics , Glatiramer Acetate , Humans , Immunosuppressive Agents/economics , Peptides/economics , United States
SELECTION OF CITATIONS
SEARCH DETAIL
...